CancerCare Center | Cancer Research

Trinity CancerCare Center: Cancer Research

Clinical Trials in CancerCare:

Trinity CancerCare offers a variety of research trials that patients have the ability to access. These research trials are essential for moving new options for preventing, diagnosing, and treating cancer from the laboratory setting to the clinic office. Below is a listing of the clinical research trials currently open for patients at Trinity CancerCare Center.

Breast Cancer:


  • BCCR: Development and implementation of the Breast Cancer Collaborative Registry: NCT00666731

  • E1Z11: A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS): NCT01824836

  • E2108: A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer: NCT01242800

  • E2112: A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer: NCT02115282

  • NSABP B-47: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer: NCT01275677

  • NSABP B-52: A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP), With or Without Estrogen Deprivation: NCT02003209

  • NSABP B-55: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy: NCT02032823

  • S1007: A Phase III, Randomized Clinical Trial Of Standard Adjuvant Endocrine Therapy +/- Chemotherapy In Patients With 1-3 Positive Nodes, Hormone Receptor-Positive And Her2-Negative Breast Cancer With Recurrence Score (Rs) Of 25 Or Less. Rxponder: A Clinical Trial Rx For Positive Node, Endocrine Responsive Breast Cancer: NCT01272037

  • S1202: A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor (AI)-Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer: NCT01598298

  • S1207: Adjuvant everolimus for high risk hormone receptor‐positive and HER2‐negative breast cancer, randomized clinical trial of standard adjuvant endocrine therapy +/‐ chemotherapy in patients with negative breast cancer with recurrence score (RS) of 25 or less: NCT01674140


Lung Cancer:


  • 1199.128 Columbus: Boehringer Ingelheim Pharmaceuticals, Inc. / Multicenter, randomized, double-blind, Phase III trial to investigate the efficacy and safety of oral nintedanib plus docetaxel therapy compared to placebo plus docetaxel therapy in patients with stage IIIB/IV or recurrent, adenocarcinoma subtype non-small cell lung cancer after failure of first line chemotherapy: NCT02231164

  • CALGB 30610: Phase III Comparison Of Thoracic Radiotherapy Regimens In Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin And Etoposide: NCT00632853

  • E5508: Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC: NCT01107626

  • RTOG 0937: Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone To Prophylactic Cranial Irradiation And Consolidative Extra-Cranial Irradiation For Extensive Disease Small Cell Lung Cancer (ED-SCLC): NCT01055197

  • S0819: A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel Or Carboplatin/Paclitaxel/Bevacizumab With Or Without Concurrent Cetuximab In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC): NCT00946712

  • S1400: Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer: NCT02154490


Hematological Cancer:


  • A041202: A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients ( ≥ 65 Years of Age) with Chronic Lymphocytic Leukemia (CLL): NCT01886872


Gastrointestinal Cancer:


  • CALGB 80702: A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer: NCT01150045

  • CALGB 80802: Phase III randomized study of sorafenib (IND 69896, NSC 724772) plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): NCT01015833

  • RTOG 1010: A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma: NCT01196390

  • S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES): NCT01349881

  • S1201: A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1 (Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric, or Gastro esophageal Junction (GEJ) Cancer: NCT01498289


Head & Neck Cancer:


  • E1305: A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab In Patients with Recurrent Or Metastatic Head and Neck Cancer: NCT00588770

  • NRG-HN001: Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA): NCT02135042


Genitourinary Cancer:


  • A031201: Phase III trial of enzalutamide (NSC # 766085) versus enzalutamide, abiraterone and prednisone for castration resistant metastatic prostate cancer: NCT01949337

  • RTOG 0815: A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer: NCT00936390

  • S0931: EVEREST: Everolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study: NCT01120145


Brain Cancer:


  • Currently no open trials.

Multiple Myeloma:


  • Currently no open trials.

Cancer with Bone Metastases:


  • Currently no open trials.

  • Contact Information for Cancer Research Trials:


    Nadia Smetana BSN, RN, CCRP
    Oncology Research Coordinator
    (701) 857-3174

    or

    Loretta Porter, RN, BSN
    Cancer Research Nurse
    (701) 857-3174

  •  
     Providers in this field:
     (hover or click to view more details)

    Michael Grant MD


    Information being updated. --More--

    Stephen Makoni MD, FACP


    As a specialist in Hematology and Oncology, Dr. Makoni provides expert care for cancer patients util --More--

    Pamela Pearson FNP-C, AOCNP


    A certified nurse practitioner, Pamela Pearson, FNP-C, AOCNP provides care as a member of Trinity He --More--

    Patanit Watanaboonyakhet DO


    Dr. Patanit Watanaboonyakhet ("Dr. Pat") specializes in Hematology and Oncology. A graduate of the U --More--